Industry Experts

Yekaterina Lin is Director of Purification Development within Biologics CMC Development at AbbVie, providing strategic and technical leadership for downstream development of monoclonal antibodies, bispecific antibodies, ADCs, and other next-generation biologics. She has over 15 years of experience advancing complex molecules from early development through commercialization, with expertise in purification process design, high-concentration biologics, manufacturability assessment, and mitigation of challenging product- and process-related risks. Her teams develop robust drug substance manufacturing strategies that enable reliable scale-up and commercial readiness while supporting accelerated development timelines. Successful development of complex biologics requires close collaboration across and outside of CMC disciplines, with the shared goal of rapidly and reliably delivering medicines to patients.